Portal de recerca
ESTUDIO PIVOTAL PARA DETERMINAR LA EFICACIA Y SEGURIDAD DE AP23573 ADMINISTRADO COMO TRATAMIENTO DE MANTENIMIENTO A PACIENTES CON SARCOMA METASTASICO OSEO O DE PARTES BLANDAS.
Dades bàsiques
- Protocol:
- AP23573-07-302
- EURDRACT:
- 2007-003462-18
- NCT:
- Centre:
- Any inici:
- Any de finalització:
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study
Frezza, Anna Maria; (...); Gronchi, Alessandro
Article. 10.1002/cam4.5015. 2022
Clinical Characteristics and Management of Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: A Feasibility Analysis of Electronic Health Records Using Natural Language Processing.
Ortiz A; (...); Rodriguez M
Article. 10.1159/000528784. 2023
Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.
Ochenduszko, Sebastian; (...); Maiques, Inmaculada Maestu
Article. 10.1111/pcmr.13093. 2023
Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002-BECARE)
Soria, A.; (...); Cerezuela-Fuentes, P.
Meeting Abstract. 10.1016/j.annonc.2023.09.2248. 2023
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
Marquez-Rodas, Ivan; (...); Berrocal, Alfonso
Article. 10.1093/neuonc/noae116. 2024
First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
Gonzalez, J. A.; (...); Lopez Pousa, A.
Meeting Abstract. 10.1016/j.annonc.2023.09.1161. 2023
First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas
Gonzalez-Lopez, Jose Antonio; (...); Pousa, Antonio Lopez
Meeting Abstract. https://doi.org/10.1016/j.annonc.2023.09.1161. 2024
ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma
Martin Broto, Javier; (...); Hindi, Nadia
Meeting Abstract. 2023
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.
Gonzalez-Cao M; (...); Berrocal A
Article. 10.1038/s41467-021-26572-6. 2021
Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial
Marquez-Rodas, I; (...); Berrocal, A
Meeting Abstract. 10.1016/j.annonc.2021.08.1423. 2021
Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer
Alvarez Gallego, R.; (...); Cubillo, A.
Meeting Abstract. 10.1016/j.annonc.2023.04.238. 2023
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).
Gronchi, Alessandro; (...); Casali, Paolo Giovanni
Article. 10.1200/JCO.23.00908. 2024
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
Pasquali, Sandro; (...); Gronchi, Alessandro
Article. 10.1002/cncr.33895. 2022
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).
Gronchi, Alessandro; (...); Casali, Paolo Giovanni
Meeting Abstract. 2022
Pancreatic cancer, Radiomics and Artificial Intelligence: A Review.
Marti-Bonmati L; (...); Alberich-Bayarri A
Article. 10.1259/bjr.20220072. 2022
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol
Salazar, Juliana; (...); Sebio, Ana
Article. 10.3390/pharmaceutics16121585. 2024
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).
Martin-Broto J; (...); Hindi N
Article. 10.1200/JCO.24.00358. 2024
Phase II trial of palbociclib in advanced sarcoma overexpressing CDK4 gene excluding dedifferentiated liposarcoma (DD LPS): A study from the Spanish Group for Research on Sarcoma (GEIS).
Broto, Javier Martin; (...); Hindi, Nadia
Meeting Abstract. 2022
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain
Alvarez-Gallego, Rafael; (...); Cubillo, Antonio
Article. 10.1177/17588359241309828. 2025
Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.
Ochenduszko, Sebastian; (...); Maestu, Inmaculada
Meeting Abstract. 2022
Redefining radiologic responses (RR) in solid tumors: Shall we brace ourselves for a post-RECIST era? Results from a randomized clinical trial (RCT) on neoadjuvant chemotherapy in high-risk soft-tissue sarcomas (HR-STS) of the trunk or extremities
Vanzulli, Andrea; (...); Gronchi, Alessandro
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.11553. 2024
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.
Vanzulli, A; (...); Gronchi, A
Article. 10.1016/j.esmoop.2025.104299. 2025
Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.
Gonzalez-Cao, Maria; (...); Berrocal, Alfonso
Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9528. 2021
RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II
Alvarez, A.; (...); Marquez Rodas, I.
Meeting Abstract. 2023
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Gounder, Mrinal M.; (...); Attia, Steven
Article. 10.1200/JCO.21.01829. 2022
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy.
Pasquali, Sandro; (...); Gronchi, Alessandro
Article. 10.1016/j.ebiom.2024.105220. 2024